Inventia Life Science Announces Third Dimension Grant for 3D Cell Culture Research

Contributed by: Business Wire

Logo

Tags

Health

Stem Cells

General Health

Research

Science

Biotechnology

Inventia Life Science

More Like This

Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development

The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of 128 days, enabling unprecedented long-term studies on drug resistance and metastasis . Ultimately, CTIONCOTEST delivers a highly predictive, 100% human-derived ethical alternative to animal testing.

Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care

RegenLab France receives prestigious EU-EIB Innovation Champion Award. Antoine Turzi, CEO and Founder of RegenLab, pictured between two officials of the European Investment Bank. (Photo: Business Wire)

RegenLab France Receives Prestigious EU-EIB Innovation Champion Award

Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking in vivo Human Colorectal Cancer Conditions and Confirming STC-1010’s Efficacy

PR Newswire associated0

Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery

PR Newswire associated0

Novadip Biosciences SA announces significant clinical milestones for both of its clinical-stage programs

PR Newswire associated0

ThinkCyte expands product portfolio to drive innovation in drug discovery and disease research.

ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research